{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:07:40Z","timestamp":1786982860040,"version":"build-2736575974"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,11,16]],"date-time":"2020-11-16T00:00:00Z","timestamp":1605484800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,11,16]],"date-time":"2020-11-16T00:00:00Z","timestamp":1605484800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Ther"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1007\/s40744-020-00250-3","type":"journal-article","created":{"date-parts":[[2020,11,16]],"date-time":"2020-11-16T15:13:32Z","timestamp":1605539612000},"page":"1021-1035","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Efficacy and Safety of Ixekizumab with or Without Methotrexate in Biologic-Na\u00efve Patients with Psoriatic Arthritis: 52-Week Results from SPIRIT-H2H Study"],"prefix":"10.1007","volume":"7","author":[{"given":"Josef S.","family":"Smolen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Sebba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric M.","family":"Ruderman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hendrik","family":"Schulze-Koops","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Sapin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda M.","family":"Gellett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aubrey Trevelin","family":"Sprabery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingnan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inmaculada","family":"de la Torre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaia","family":"Gallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soyi","family":"Liu-Leage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sreekumar","family":"Pillai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulo","family":"Reis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Nash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,16]]},"reference":[{"issue":"1","key":"250_CR1","doi-asserted-by":"publisher","first-page":"65","DOI":"10.7861\/clinmedicine.17-1-65","volume":"17","author":"LC Coates","year":"2017","unstructured":"Coates LC, Helliwell PS. Psoriatic arthritis: state of the art review. Clin Med. 2017;17(1):65\u201370.","journal-title":"Clin Med"},{"issue":"10","key":"250_CR2","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1056\/NEJMra1505557","volume":"376","author":"CT Ritchlin","year":"2017","unstructured":"Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. N Engl J Med. 2017;376(10):957\u201370.","journal-title":"N Engl J Med"},{"issue":"Suppl 2","key":"250_CR3","first-page":"ii14-7","volume":"64","author":"DD Gladman","year":"2005","unstructured":"Gladman DD, Antoni C, Mease P, et al. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis. 2005;64(Suppl 2):ii14-7.","journal-title":"Ann Rheum Dis"},{"key":"250_CR4","first-page":"CD012722","volume":"1","author":"TD Wilsdon","year":"2019","unstructured":"Wilsdon TD, Whittle SL, Thynne TR, et al. Methotrexate for psoriatic arthritis. Cochrane Database Syst Rev. 2019;1:CD012722.","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"250_CR5","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1136\/annrheumdis-2020-217159","volume":"79","author":"L Gossec","year":"2020","unstructured":"Gossec L, Baraliakos X, Kerschbaumer A, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis. 2020;79(6):700\u201312.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"250_CR6","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1136\/annrheumdis-2015-208337","volume":"75","author":"L Gossec","year":"2016","unstructured":"Gossec L, Smolen JS, Ramiro S, et al. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis. 2016;75(3):499\u2013510.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"250_CR7","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.rdc.2019.04.007","volume":"45","author":"W Ye","year":"2019","unstructured":"Ye W, Coates LC. Should methotrexate have any place in the treatment of psoriatic arthritis? Rheum Dis Clin North Am. 2019;45(3):325\u201339.","journal-title":"Rheum Dis Clin North Am"},{"issue":"10012","key":"250_CR8","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1016\/S0140-6736(15)00347-5","volume":"386","author":"LC Coates","year":"2015","unstructured":"Coates LC, Moverley AR, McParland L, et al. Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial. Lancet. 2015;386(10012):2489\u201398.","journal-title":"Lancet"},{"issue":"7","key":"250_CR9","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1002\/art.40851","volume":"71","author":"PJ Mease","year":"2019","unstructured":"Mease PJ, Gladman DD, Collier DH, et al. Etanercept and methotrexate as monotherapy or in combination for psoriatic arthritis: primary results from a randomized, controlled phase III trial. Arthritis Rheumatol. 2019;71(7):1112\u201324.","journal-title":"Arthritis Rheumatol"},{"issue":"7","key":"250_CR10","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1002\/art.41274","volume":"72","author":"A Kerschbaumer","year":"2020","unstructured":"Kerschbaumer A, Smolen JS, Aletaha D, et al. Is methotrexate as efficacious as etanercept in psoriatic arthritis patients? Comment on the article by Mease et al. Arthritis Rheumatol. 2020;72(7):1227\u20139.","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"250_CR11","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1093\/rheumatology\/keu415","volume":"54","author":"F Behrens","year":"2015","unstructured":"Behrens F, Canete JD, Olivieri I, et al. Tumour necrosis factor inhibitor monotherapy vs combination with MTX in the treatment of PsA: a systematic review of the literature. Rheumatology. 2015;54(5):915\u201326.","journal-title":"Rheumatology"},{"issue":"3","key":"250_CR12","doi-asserted-by":"publisher","first-page":"632","DOI":"10.3899\/jrheum.141596","volume":"43","author":"F Behrens","year":"2016","unstructured":"Behrens F, Koehm M, Arndt U, et al. Does concomitant methotrexate with adalimumab influence treatment outcomes in patients with psoriatic arthritis? Data from a large observational study. J Rheumatol. 2016;43(3):632\u20139.","journal-title":"J Rheumatol"},{"issue":"4","key":"250_CR13","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1002\/art.21655","volume":"54","author":"D van der Heijde","year":"2006","unstructured":"van der Heijde D, Klareskog L, Rodriguez-Valverde V, et al. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. Arthritis Rheum. 2006;54(4):1063\u201374.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"250_CR14","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1002\/art.21519","volume":"54","author":"FC Breedveld","year":"2006","unstructured":"Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 2006;54(1):26\u201337.","journal-title":"Arthritis Rheum"},{"issue":"9685","key":"250_CR15","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/S0140-6736(09)60506-7","volume":"374","author":"JS Smolen","year":"2009","unstructured":"Smolen JS, Kay J, Doyle MK, et al. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet. 2009;374(9685):210\u201321.","journal-title":"Lancet"},{"issue":"9","key":"250_CR16","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1136\/annrheumdis-2018-213416","volume":"77","author":"Y Kaneko","year":"2018","unstructured":"Kaneko Y, Kato M, Tanaka Y, et al. Tocilizumab discontinuation after attaining remission in patients with rheumatoid arthritis who were treated with tocilizumab alone or in combination with methotrexate: results from a prospective randomised controlled study (the second year of the SURPRISE study). Ann Rheum Dis. 2018;77(9):1268\u201375.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"250_CR17","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1136\/annrheumdis-2013-204761","volume":"73","author":"M Dougados","year":"2014","unstructured":"Dougados M, Kissel K, Conaghan PG, et al. Clinical, radiographic and immunogenic effects after 1 year of tocilizumab-based treatment strategies in rheumatoid arthritis: the ACT-RAY study. Ann Rheum Dis. 2014;73(5):803\u20139.","journal-title":"Ann Rheum Dis"},{"key":"250_CR18","doi-asserted-by":"publisher","first-page":"39","DOI":"10.2147\/JIR.S100940","volume":"9","author":"L Liu","year":"2016","unstructured":"Liu L, Lu J, Allan BW, et al. Generation and characterization of ixekizumab, a humanized monoclonal antibody that neutralizes interleukin-17A. J Inflamm Res. 2016;9:39\u201350.","journal-title":"J Inflamm Res"},{"issue":"1","key":"250_CR19","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1080\/14712598.2018.1410133","volume":"18","author":"E Toussirot","year":"2018","unstructured":"Toussirot E. Ixekizumab: an anti- IL-17A monoclonal antibody for the treatment of psoriatic arthritis. Expert Opin Biol Ther. 2018;18(1):101\u20137.","journal-title":"Expert Opin Biol Ther"},{"key":"250_CR20","doi-asserted-by":"crossref","unstructured":"Paller AS, Seyger MM, Magari\u00f1os G, et al. Efficacy and safety of ixekizumab in a phase 3, randomized, double-blind, placebo-controlled study in paediatric patients with moderate-to-severe plaque psoriasis (IXORA-PEDS) Br J Dermatol. 2020;183(2):231\u201341.","DOI":"10.1111\/bjd.19147"},{"key":"250_CR21","unstructured":"Eli Lilly and Company. Highlights of prescribing information\u2014Taltz. 2020. https:\/\/uspl.lilly.com\/taltz\/taltz.html#pi."},{"issue":"1","key":"250_CR22","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1136\/annrheumdis-2019-215386","volume":"79","author":"PJ Mease","year":"2020","unstructured":"Mease PJ, Smolen JS, Behrens F, et al. A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naive patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial. Ann Rheum Dis. 2020;79(1):123\u201331.","journal-title":"Ann Rheum Dis"},{"key":"250_CR23","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1136\/annrheumdis-2020-217372","volume":"79","author":"JS Smolen","year":"2020","unstructured":"Smolen JS, Mease P, Tahir H, et al. Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis naive to biological disease-modifying antirheumatic drug: final results by week 52. Ann Rheum Dis. 2020;79:1310\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"250_CR24","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1002\/art.21306","volume":"52","author":"PJ Mease","year":"2005","unstructured":"Mease PJ, Gladman DD, Ritchlin CT, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2005;52(10):3279\u201389.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"250_CR25","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1002\/art.22379","volume":"56","author":"DD Gladman","year":"2007","unstructured":"Gladman DD, Mease PJ, Ritchlin CT, et al. Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial. Arthritis Rheum. 2007;56(2):476\u201388.","journal-title":"Arthritis Rheum"},{"issue":"5","key":"250_CR26","doi-asserted-by":"publisher","first-page":"361","DOI":"10.3109\/09546634.2012.751483","volume":"24","author":"JM van den Reek","year":"2013","unstructured":"van den Reek JM, van Lumig PP, Kievit W, et al. Effectiveness of adalimumab dose escalation, combination therapy of adalimumab with methotrexate, or both in patients with psoriasis in daily practice. J Dermatolog Treat. 2013;24(5):361\u20138.","journal-title":"J Dermatolog Treat"},{"key":"250_CR27","unstructured":"AbbVie Inc. Highlights of prescribing information\u2014Humira. 2020. https:\/\/www.rxabbvie.com\/pdf\/humira.pdf."},{"issue":"10235","key":"250_CR28","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1016\/S0140-6736(20)30564-X","volume":"395","author":"IB McInnes","year":"2020","unstructured":"McInnes IB, Behrens F, Mease PJ, et al. Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial. Lancet. 2020;395(10235):1496\u2013505.","journal-title":"Lancet"}],"container-title":["Rheumatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-020-00250-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40744-020-00250-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-020-00250-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,15]],"date-time":"2020-12-15T07:50:45Z","timestamp":1608018645000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40744-020-00250-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,16]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["250"],"URL":"https:\/\/doi.org\/10.1007\/s40744-020-00250-3","relation":{},"ISSN":["2198-6576","2198-6584"],"issn-type":[{"value":"2198-6576","type":"print"},{"value":"2198-6584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,16]]},"assertion":[{"value":"11 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}